BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ARO-ALK7 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ARO-ALK7\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06937203-173@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ARO-ALK7: Phase 1/2 readout est. (NCT06937203)
DESCRIPTION:ARO-ALK7\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study 
 of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellit
 us\nEstimated primary completion: February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/aro-alk7#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06937203
URL:https://assetmemo.bio/drug/aro-alk7#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
